Artivion Inc AORT

NYS: AORT | ISIN: US2289031005   20/03/2026
35,31 USD (-3,34%)
(-3,34%)   20/03/2026

3 maart 2026 · Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference · Persbericht

12 februari 2026 · Artivion Reports Fourth Quarter and Full Year 2025 Financial Results · Persbericht

2 februari 2026 · Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting · Persbericht

29 januari 2026 · Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results · Persbericht

6 november 2025 · Artivion Reports Third Quarter 2025 Financial Results · Persbericht

6 november 2025 · Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial · Persbericht

29 oktober 2025 · Artivion to Participate in the Stifel 2025 Healthcare Conference · Persbericht

23 oktober 2025 · Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results · Persbericht

13 oktober 2025 · Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE and AMDS PROTECT Trials at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting · Persbericht

5 september 2025 · Artivion to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference · Persbericht

7 augustus 2025 · Artivion Reports Second Quarter 2025 Financial Results · Persbericht

30 juli 2025 · Artivion to Participate in Upcoming Investor Conferences · Persbericht

24 juli 2025 · Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results · Persbericht

3 juni 2025 · Artivion to Participate in Upcoming Investor Conferences · Persbericht

28 mei 2025 · Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock · Persbericht

14 mei 2025 · Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock · Persbericht

5 mei 2025 · Artivion Reports First Quarter 2025 Financial Results · Persbericht

5 mei 2025 · Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting · Persbericht

21 april 2025 · Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results · Persbericht

4 maart 2025 · Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference · Persbericht

Mijn selecties